Results 281 to 286 of about 36,503 (286)
Some of the next articles are maybe not open access.
Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide*
Clinical Pharmacology & Therapeutics, 1997To investigate the interaction between fluvoxamine and chloroguanide (INN, proguanil) to confirm that fluvoxamine inhibits CYP2C19.The study was carried out with a randomized, in vivo, crossover design. Six volunteers were extensive metabolizers of the S-mephenytoin oxidation polymorphism, and six volunteers were poor metabolizers.
Jeppesen, Unni +2 more
openaire +4 more sources
Prevalence of CYP2C19 polymorphisms in the Lebanese population
Molecular Biology Reports, 2011Clopidogrel is one of the most commonly prescribed drugs, as its combination with low-dose aspirin is the recommended oral anti-platelet therapy, to prevent ischaemic events following coronary syndromes or stent placement. Numerous recent studies have shown that polymorphisms in the gene encoding the cytochrome P450 (CYP450) 2C19 enzyme (CYP2C19 ...
Sose Keleshian +5 more
openaire +3 more sources
The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway
The Journal of Clinical Pharmacology, 2016AbstractThe major metabolic pathway of clopidogrel is conversion to carboxylic acid by an esterase (CES1), forming clopidogrelic acid (SR26334) that is inactive. There is agreement on the structure of the active metabolite; however, there are differing views about the mechanism of its formation.
openaire +3 more sources
CYP2C19*2 and CYP2C19*3 allelomorphism in Turkish population
International Journal of Cardiology, 2017openaire +4 more sources
Allele frequency of CYP2C19 in a Portuguese population
Pharmacogenetics, 1997Maria Celeste Lechner, Jorge L. Ruas
openaire +3 more sources
InFo Neurologie & Psychiatrie, 2019